Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovaxin Phase 1/2 Dose Escalation in MS
NCT00587691Phase 2Completed
- Sponsor
- Opexa Therapeutics
- Start
- Jul 2002
- Primary completion
- Jun 2007
- Modality
- Native Immune Cells, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tovaxin in multiple sclerosis (MS), sponsored by Opexa Therapeutics. Started Jul 2002; status: completed.
02
Drugs
tovaxin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00587691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00587691.